Terlipressin-AFT

Bleeding oesophageal varices (BOV). Patients w/ hepatorenal syndrome (HRS) type 1 who are actively being considered for liver transplant.

IV Adult BOV Initially 2 vials every 4 hr. Maintain until bleeding has been controlled for 24 hr, but up to a max of 48 hr. May be adjusted to 1 vial every 4 hr after initial dose in patients weighing <50 kg or if adverse effects occur. HRS 1 vial every 6-12 hr by slow IV bolus inj for 7-14 days (administered in association w/ albumin 20% 100 mL IV bd for 7-14 days). May be increased to a max of 2 vials every 6 hr if serum creatinine (SCr) has not decreased by at least 30% from the baseline value after 3 days. Patient w/ severe pre-existing CV disease or in the presence of an ongoing significant adverse event (eg, pulmonary oedema, ischaemia) Continue until about 2 days after the patient achieves HRS reversal (SCr ≤132.6 micromol/L), or discontinue if the patient undergoes dialysis or liver transplant or if SCr remains at or above baseline after 7 days of treatment. Alternative to bolus inj May be administered as a continuous IV infusion w/ a starting dose of 2 mg/24 hr & increased to a max of 12 mg/24 hr.

Hypersensitivity. Pregnancy.

Haemostatics

H01BA04 - terlipressin ; Belongs to the class of vasopressin and analogues. Used in posterior pituitary lobe hormone preparations.

POM